Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Allison Barraclough; Catherine Tang; Masa Lasica; Elizabeth Smyth; Melita Cirillo; Howard Mutsando; Chan Y. Cheah; Matthew Ku

doi:10.1111/imj.16561

Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Allison Barraclough, Catherine Tang, Masa Lasica, Elizabeth Smyth, Melita Cirillo, Howard Mutsando, Chan Y. Cheah, Matthew Ku

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell neoplasm with unique clinicopathological features, accounting for 5% of all non-Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes. This review details the recent advances in the understanding of MCL biology and outlines the recommended diagnostic strategies and evidence-based approaches to treatment.

Original language	English
Pages (from-to)	117-129
Number of pages	13
Journal	Internal Medicine Journal
Volume	55
Issue number	1
DOIs	https://doi.org/10.1111/imj.16561
Publication status	Published - Jan 2025
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2024 Royal Australasian College of Physicians.

Keywords

disease management
lymphoma
mantle cell lymphoma
non-Hodgkin lymphoma
practice guideline

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/imj.16561

Cite this

@article{d4687854967348418004bf097d4ec43a,

title = "Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance",

abstract = "Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell neoplasm with unique clinicopathological features, accounting for 5% of all non-Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes. This review details the recent advances in the understanding of MCL biology and outlines the recommended diagnostic strategies and evidence-based approaches to treatment.",

keywords = "disease management, lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, practice guideline",

author = "Allison Barraclough and Catherine Tang and Masa Lasica and Elizabeth Smyth and Melita Cirillo and Howard Mutsando and Cheah, {Chan Y.} and Matthew Ku",

note = "Publisher Copyright: {\textcopyright} 2024 Royal Australasian College of Physicians.",

year = "2025",

month = jan,

doi = "10.1111/imj.16561",

language = "English",

volume = "55",

pages = "117--129",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley and Sons Inc",

number = "1",

}

TY - JOUR

T1 - Diagnosis and management of mantle cell lymphoma

T2 - a consensus practice statement from the Australasian Lymphoma Alliance

AU - Barraclough, Allison

AU - Tang, Catherine

AU - Lasica, Masa

AU - Smyth, Elizabeth

AU - Cirillo, Melita

AU - Mutsando, Howard

AU - Cheah, Chan Y.

AU - Ku, Matthew

PY - 2025/1

Y1 - 2025/1

N2 - Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell neoplasm with unique clinicopathological features, accounting for 5% of all non-Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes. This review details the recent advances in the understanding of MCL biology and outlines the recommended diagnostic strategies and evidence-based approaches to treatment.

AB - Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell neoplasm with unique clinicopathological features, accounting for 5% of all non-Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes. This review details the recent advances in the understanding of MCL biology and outlines the recommended diagnostic strategies and evidence-based approaches to treatment.

KW - disease management

KW - lymphoma

KW - mantle cell lymphoma

KW - non-Hodgkin lymphoma

KW - practice guideline

UR - http://www.scopus.com/inward/record.url?scp=85209989805&partnerID=8YFLogxK

U2 - 10.1111/imj.16561

DO - 10.1111/imj.16561

M3 - Article

AN - SCOPUS:85209989805

SN - 1444-0903

VL - 55

SP - 117

EP - 129

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 1

ER -

Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this